Venexia M Walker1,2, Patrick G Kehoe3,4, Richard M Martin1,2, Neil M Davies1,2. 1. Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, UK. 2. Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UK. 3. Dementia Research Group, University of Bristol, Bristol, UK. 4. Bristol Medical School: Translational Health Sciences, University of Bristol, Bristol, UK.
Abstract
BACKGROUND: Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease. METHODS: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. RESULTS: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p = 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p = 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p = 0.45; SNPs = 153). CONCLUSIONS: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.
BACKGROUND: Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease. METHODS: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. RESULTS: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p = 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p = 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p = 0.45; SNPs = 153). CONCLUSIONS: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.
Authors: Sevil Yasar; Jin Xia; Wenliang Yao; Curt D Furberg; Qian-Li Xue; Carla I Mercado; Annette L Fitzpatrick; Linda P Fried; Claudia H Kawas; Kaycee M Sink; Jeff D Williamson; Steven T DeKosky; Michelle C Carlson Journal: Neurology Date: 2013-08-02 Impact factor: 9.910
Authors: Anne Corbett; James Pickett; Alistair Burns; Jonathan Corcoran; Stephen B Dunnett; Paul Edison; Jim J Hagan; Clive Holmes; Emma Jones; Cornelius Katona; Ian Kearns; Patrick Kehoe; Amrit Mudher; Anthony Passmore; Nicola Shepherd; Frank Walsh; Clive Ballard Journal: Nat Rev Drug Discov Date: 2012-11 Impact factor: 84.694
Authors: Debbie A Lawlor; Roger M Harbord; Jonathan A C Sterne; Nic Timpson; George Davey Smith Journal: Stat Med Date: 2008-04-15 Impact factor: 2.373
Authors: Søren D Østergaard; Shubhabrata Mukherjee; Stephen J Sharp; Petroula Proitsi; Luca A Lotta; Felix Day; John R B Perry; Kevin L Boehme; Stefan Walter; John S Kauwe; Laura E Gibbons; Eric B Larson; John F Powell; Claudia Langenberg; Paul K Crane; Nicholas J Wareham; Robert A Scott Journal: PLoS Med Date: 2015-06-16 Impact factor: 11.069
Authors: Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis Journal: Nature Date: 2015-10-01 Impact factor: 49.962
Authors: Brian Lawlor; Ricardo Segurado; Sean Kennelly; Marcel G M Olde Rikkert; Robert Howard; Florence Pasquier; Anne Börjesson-Hanson; Magda Tsolaki; Ugo Lucca; D William Molloy; Robert Coen; Matthias W Riepe; János Kálmán; Rose Anne Kenny; Fiona Cregg; Sarah O'Dwyer; Cathal Walsh; Jessica Adams; Rita Banzi; Laetitia Breuilh; Leslie Daly; Suzanne Hendrix; Paul Aisen; Siobhan Gaynor; Ali Sheikhi; Diana G Taekema; Frans R Verhey; Raffaello Nemni; Flavio Nobili; Massimo Franceschi; Giovanni Frisoni; Orazio Zanetti; Anastasia Konsta; Orologas Anastasios; Styliani Nenopoulou; Fani Tsolaki-Tagaraki; Magdolna Pakaski; Olivier Dereeper; Vincent de la Sayette; Olivier Sénéchal; Isabelle Lavenu; Agnès Devendeville; Gauthier Calais; Fiona Crawford; Michael Mullan Journal: PLoS Med Date: 2018-09-24 Impact factor: 11.069
Authors: Daniel I Swerdlow; Karoline B Kuchenbaecker; Sonia Shah; Reecha Sofat; Michael V Holmes; Jon White; Jennifer S Mindell; Mika Kivimaki; Eric J Brunner; John C Whittaker; Juan P Casas; Aroon D Hingorani Journal: Int J Epidemiol Date: 2016-06-24 Impact factor: 7.196
Authors: Michael G Levin; Derek Klarin; Venexia M Walker; Dipender Gill; Julie Lynch; Jacklyn N Hellwege; Jacob M Keaton; Kyung M Lee; Themistocles L Assimes; Pradeep Natarajan; Adriana M Hung; Todd L Edwards; Daniel J Rader; J Michael Gaziano; Neil M Davies; Philip S Tsao; Kyong-Mi Chang; Benjamin F Voight; Scott M Damrauer Journal: Arterioscler Thromb Vasc Biol Date: 2021-04-15 Impact factor: 10.514
Authors: Denis A Baird; Jimmy Z Liu; Jie Zheng; Solveig K Sieberts; Thanneer Perumal; Benjamin Elsworth; Tom G Richardson; Chia-Yen Chen; Minerva M Carrasquillo; Mariet Allen; Joseph S Reddy; Philip L De Jager; Nilufer Ertekin-Taner; Lara M Mangravite; Ben Logsdon; Karol Estrada; Philip C Haycock; Gibran Hemani; Heiko Runz; George Davey Smith; Tom R Gaunt Journal: PLoS Genet Date: 2021-01-08 Impact factor: 5.917
Authors: Dipender Gill; Marios K Georgakis; Venexia M Walker; A Floriaan Schmidt; Apostolos Gkatzionis; Daniel F Freitag; Chris Finan; Aroon D Hingorani; Joanna M M Howson; Stephen Burgess; Daniel I Swerdlow; George Davey Smith; Michael V Holmes; Martin Dichgans; Robert A Scott; Jie Zheng; Bruce M Psaty; Neil M Davies Journal: Wellcome Open Res Date: 2021-02-10
Authors: Heming Wang; Nuzulul Kurniansyah; Brian E Cade; Matthew O Goodman; Han Chen; Daniel J Gottlieb; Sina A Gharib; Shaun M Purcell; Xihong Lin; Richa Saxena; Xiaofeng Zhu; Peter Durda; Russel Tracy; Yongmei Liu; Kent D Taylor; W Craig Johnson; Stacey Gabriel; Joshua D Smith; François Aguet; Kirstin Ardlie; Tom Blackwell; Alexander P Reiner; Jerome I Rotter; Stephen S Rich; Susan Redline; Tamar Sofer Journal: Sci Rep Date: 2022-01-27 Impact factor: 4.996
Authors: Michael G Levin; Verena Zuber; Venexia M Walker; Derek Klarin; Julie Lynch; Rainer Malik; Aaron W Aday; Leonardo Bottolo; Aruna D Pradhan; Martin Dichgans; Kyong-Mi Chang; Daniel J Rader; Philip S Tsao; Benjamin F Voight; Dipender Gill; Stephen Burgess; Scott M Damrauer Journal: Circulation Date: 2021-06-18 Impact factor: 29.690
Authors: Matthew C Hyman; Michael G Levin; Dipender Gill; Venexia M Walker; Marios K Georgakis; Neil M Davies; Francis E Marchlinski; Scott M Damrauer Journal: Hypertension Date: 2021-01-04 Impact factor: 10.190